R E V I E W

Suitability of Measures of Pharmacy-Based Medication Adherence for Routine Clinical Use Among Patients with Chronic Diseases: A Systematic Review

Wardatul Jannah 🔟[1,2], Qisty A Khoiry 🔟[1,2], Sofa D Alfian 🔟[1,2], Rizky Abdulah[1,2]

[1]Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia; [2]Drug Utilization and Pharmacoepidemiology Research Group, Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jatinangor, Indonesia

Correspondence: Sofa D Alfian, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Jatinangor, KM 21, Jatinangor, Sumedang, Indonesia, Tel/Fax +62-022-7796200, Email sofa.alfian@unpad.ac.id

Purpose: To identify the suitability of pharmacy-based measures for determining medication adherence in routine clinical use.

Methods: Data were obtained through PubMed and Scopus databases up to December 2023 without publication year restrictions. This review included English studies on assessing medication adherence for hypertension, hyperlipidemia, asthma, chronic obstructive pulmonary disease, and diabetes, using pharmacy databases and providing full-text access. We investigated evidence quality utilizing the Newcastle–Ottawa Scale for non-randomized studies (cohort, case-control, and cross-sectional) and the Risk of Bias Assessment Tool for Non-randomized Studies-2 and JADAD scales for quasi-experiments and randomized control trials, respectively. We determined validity characteristics (completeness, accuracy, reliability, objectivity, continuous adherence history, non-intrusiveness, sensitivity, and specificity) and applicability (cost-effectiveness, ease of use, and interpretability) to evaluate the suitability of pharmacy-based medication adherence measures in clinical settings.

Results: This review retrieved 1513 studies, of which 74 met the inclusion criteria. All of the studies, which were published from 2000 to 2023 and mostly utilized a retrospective cohort design (n = 53), included 17.6 million patients. Of the 74 studies, 50 were conducted in the United States. Diabetes mellitus (n = 40) was the most prevalent disease, whereas the medication possession ratio (n = 46) and prescription days covered (n = 31) were the most prevalent pharmacy-based matrix. According to the results, 73 articles demonstrated validity characteristics, whereas 1 article lacked these characteristics. All 74 (100%) articles had applicability characteristics.

Conclusion: This systematic review demonstrates that pharmacy-based measures possess valid characteristics, including comprehensive, accurate, objective, reliable, and continuously updated adherence history records. These measures are designed to minimize disruption while offering high sensitivity and specificity. Furthermore, they are characterized by their practicality, being cost-effective, easy to implement, and easy to interpret. These findings suggest that pharmacy-based measures are potentially suitable to assess medication adherence for routine clinical use.

Keywords: medication possession ratio, proportion of days covered, pharmacy fill, medication adherence, chronic disease, suitability, validity, applicability, routine clinical use

Introduction

Chronic diseases have been the leading cause of death globally.[1] Data from the World Health Organization reveal that annually, chronic diseases cause deaths in 41 million individuals, equivalent to 74% of total deaths globally.[1] Low-middle-income countries (LMIC) reported the highest mortality rate of 77% caused by chronic noncommunicable diseases.[2] Hypertension, chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), and asthma are chronic noncommunicable diseases with high prevalence globally.[3–8] Poor adherence to prescribed medication is a widespread health problem in chronic disease management, with evidence from multiple studies across different countries consistently indicating suboptimal adherence rates.[9–12] The effect is particularly severe, causing therapeutic failure, reduced

quality of life, comorbidity development, and increased mortality.[13–18] Healthcare professionals, particularly pharmacists, need to address this issue during clinical practice.[19]

Pharmacists are one of the health professionals with a crucial role in managing patients with medication adherence.[19,20] Furthermore, community pharmacists have the expertise to determine and address medication-related problems and have substantial clinical knowledge of medications.[19] Several studies have been conducted on the role of pharmacists in improving medication adherence.[19,21,22] For example, particular research revealed that pharmacist-provided interventions were successful in improving medication adherence with implications for enhanced patient clinical outcomes.[23] The results of measuring medication adherence serve as the basis for developing appropriate interventions. However, in reality, obtaining accurate measurement data and practicing medication adherence measurement in clinical practice remains challenging to implement.[24] Pharmacists have various requirements, including requiring visualization of medication adherence measurement results that are easy to interpret and can be seen by patients themselves, measurement data that can be sent easily through online media, and fast tools in detecting the medication adherence level.[25]

Currently, several tools are used to measure patient medication adherence; one of the most prevalently used tools is self-report.[26–28] Based on a scoping review conducted by Khoiry et al (2023), the Morisky Medication Adherence Scale-8 (MMAS-8) is the most popularly used self-report instrument, especially in LMIC.[27] Self-reporting provides many benefits, including ease of use, inexpensive, and the ability to observe behaviors and barriers related to medication adherence,[26,27,29] but it has significant drawbacks, such as recall bias, inability to accurately evaluate medication timing or patterns, adherence overestimation, and low sensitivity.[28,29] These shortcomings are significant issues as they affect the accuracy of evaluating medication adherence. Additionally, ideally, medication adherence measurement tools should be accurate.[30] Using pharmacy-based medication adherence evaluation is potentially an appropriate way to address these shortcomings. This method provides many advantages, including avoiding recall bias through real-world data, the ability to assess medication adherence through retrospective data, minimal ethical concerns, low cost, wide population applicability, and shorter measurement duration.[30–32]

A previous literature review revealed that measuring medication adherence with pharmacy-based data are suitable for measuring medication adherence. However, this review does not serve as a formal evidence-based guideline but rather only guides future research and clinical practice for healthcare professionals.[33] Studies that evaluate the suitability of adopting pharmacy-based medication adherence measures for routine clinical use are warranted to address the limitations of self-report instruments and the potential of pharmacy-based measures to meet the requirements of pharmacists in clinical use. The present systematic review aimed to evaluate the suitability of pharmacy-based measures for routine clinical use.

Material and Methods

This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[34] while reporting a comprehensive systematic review of the selected research.

Information Sources and Search Strategy

The electronic databases, namely PubMed and Scopus, were searched until December 2023. The entire search strategy utilized a combination of medical subject heading terms, as stated in Table S1. Additionally, no publication year restrictions were considered to determine research suitable for evaluating medication adherence with pharmacy-based measures for routine clinical use. The selected research was published in English and measured medication adherence in five major diseases, including hypertension, hyperlipidemia, asthma, COPD, and DM, using pharmacy-based measures, as well as full-text availability.

This study excluded research that lacked abstracts, conferences, and proceedings. Additionally, articles that could not be accessed in full text after requesting access from the author were also excluded. Participants with multi-comorbidities and medication adherence measurements performed utilizing an insurance database were excluded. This was because measuring medication adherence with a pharmacy database was expected to be more accurate than with an insurance claims database.[35] Further, research focused on persistently measuring medication adherence was excluded. We defined the suitability of pharmacy-based medication adherence measures in routine clinical use by observing validity and applicability characteristics.[36,37] The characteristics that define a valid measure of medication adherence consist of multiple factors, including completeness and accuracy, thereby providing a reliable and objective assessment, having a continuous record of adherence history, being non-

intrusive to prevent affecting patient behavior, and demonstrating high sensitivity and specificity or exhibiting a statistically significant correlation.[36,37] The characteristics that improve applicability include being inexpensive, easy to use, and easy to interpret.[36,37]

Selection Process

In the first phase, WJ independent reviewers evaluated the eligibility of the research based on the title and abstract with a web-based tool called Rayyan.ai.new.[38] In the second phase of the screening process, WJ retrieved and reviewed the full text of the potentially eligible articles. Any doubt in the screening process was resolved through consensus with the QAK. Disagreements were resolved by consensus with a third reviewer, RA. Furthermore, WJ extracted data from the selected articles, and any doubts from the extraction process were resolved through consensus with SDA.

Data Collection Process

A data extraction sheet was established to extract research characteristics and information associated with the suitability of pharmacy-based measures, namely disease type, validity, and applicability. The sheet was subsequently pilot-tested utilizing five randomly selected analyses, with WJ, the reviewer, independently conducting a comprehensive data extraction. Additionally, the QAK reviewer assesses the data extraction process and addresses any uncertainties that arise.

Quality Assessment

WJ conducts the quality evaluation process independently. The QAK reviewer assesses the quality assessment. The quality assessment of both the cohort and case-control research designs was conducted with the Newcastle–Ottawa scale (NOS). This comprised four questions focused on group selection quality, one on group comparability, and three on case-control and cohort investigation exposure or outcome. The research was awarded a maximum of one star for each numbered question in the Selection and Outcomes categories. A maximum of two stars were awarded for comparability. The scoring results were interpreted as follows. Good quality: 3 or 4 stars in the selection domain, 1 or 2 stars in the comparability domain, and 2 or 3 stars in the outcome/exposure domain. Fair quality: 2 stars in the selection domain, 1 or 2 stars in the comparability domain, and 2 or 3 stars in the outcome/exposure domain. Poor quality: 0 or 1 star in the selection domain, 0 stars in the comparability domain, and 0 or 1 star in the outcome/exposure domain.[39] However, the modified NOS was utilized to evaluate the cross-sectional research design.[40] The NOS was adapted from the Newcastle–Ottawa Quality Assessment Scale for cohort investigations to provide a quality assessment of cross-sectional research. Furthermore, the star scoring in the selection, comparability, and outcome domains was a maximum total of 5 stars, 2 stars, and 3 stars, respectively. The assessment interpretation given is very good research: 9–10 stars, good research: 7–8 stars, satisfactory research: 5–6 stars, and unsatisfactory research: 0–4 stars.[3]

The modified JADAD Scale was used in research with a randomized control trials (RCTs) design.[41] This scale was calculated utilizing six items, with one point allocated for an agreed answer or zero points for a disagreed answer for each question. The possible score range is 0–5, with 3–5 and 0–2 scores indicating good and poor qualities, respectively.[41] The quality assessment tool we utilize for quasi-experimental research is the revised Risk of Bias Assessment Tool for Non-randomized Studies-2 (RoBANS-2).[42] This tool consists of eight domains, namely, target group comparability, target group selection, confounding, intervention/exposure measurement, assessor bias, outcome assessment, incomplete outcome data, and non-selective outcome reporting. The risk of bias assessments were low, high, and unclear.[42]

Results
Study Selection

Figure 1 illustrates that 1,513 articles were obtained from database sources, consisting of PubMed (n = 779) and Scopus (n = 734). Duplication checks were conducted utilizing the Rayyan.ai.new tool,[38] resulting in the realization of 301 duplicates. Subsequently, 1,212 articles were subjected to title and abstract screening using Rayyan.ai.new tool.[38] Furthermore, 913 articles were excluded because they did not meet the inclusion criteria with the following information, review articles, commentaries, conference proceedings, and book chapters (n = 127), using insurance databases (n = 126), treatment adherence was evaluated in patients without DM, hypertension, COPD, hyperlipidemia, and asthma (n = 546), pharmacy-based measures were not used (n = 18), and

Figure 1 PRISMA Flow Diagram. Adapted from Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021; 372 :n71. Creative Commons.

adherence was not assessed (n = 96). This resulted in the realization of 299 articles, which proceeded to the full-text screening. In this phase, five articles were excluded from this study because of unavailable full texts. A contact was attempted, but no feedback was received. However, of the 294 articles screened at the full-text level, 220 were excluded from not meeting the inclusion criteria. The reasons for exclusion were as follows: persistence and medication gap measurement (n = 37), subjects with multi-comorbidities (n = 157), medication adherence as not the primary outcome (n = 10), not published in English (n = 1), and using an insurance database (n = 15). This research included the remaining 74 that met the inclusion criteria. The PRISMA flow diagram in Figure 1 illustrates the determined and excluded research at each stage of the review.

Characteristics of the Included Studies

Table S2 presents the general characteristics of the 74 articles[43–115] that met the inclusion criteria. Most of the analyses (n = 53) were retrospective cohort investigations, such as RCTs (n = 10), cross-sectional (n = 5), quasi-experimental (n = 4), pragmatic clinical trials (n = 1), and nested case-control (n = 1). A total of 74 articles were published from 2000 to 2023, encompassing 50 studies conducted across the United States. Among these, 13 studies were conducted in unspecified states, whereas 7 were located in Texas, 4 in New York, and 5 in Colorado and Oregon. Additionally, three studies were conducted in Washington; two studies were conducted in each of the states of Puerto Rico, Maryland, and California; one study was conducted in each of the following states: Alabama, Utah, Minnesota, Pennsylvania, and South Carolina, as well as in the Virgin Islands and Wisconsin; some studies were conducted in more than one state (Table S2). Furthermore, research was performed in several other countries, including 7 in Canada, 3 each in Malaysia, the Netherlands, and the United Kingdom, 2 each in Australia and

New Zealand, and 1 each in Colombia, France, Hong Kong, India, Indiana, Indonesia, Portugal, Sierra Leone, Singapore, South Africa, Brazil, and Sweden (Table S2). Approximately 17.6 million patients were included in these studies.[43–116] All the research reviewed utilized real-world data from pharmacy claims databases. The reviews on disease types frequently evaluated using the pharmacy-based measure of medication adherence included DM in 40 articles, followed by hypertension (n = 27), asthma (n = 17), hyperlipidemia (n = 16), and COPD (n = 2). However, some research focused on measuring medication adherence for more than one disease (Table S2).

The pharmacy-based measure of medication adherence was conducted with several matrix types. The most preva-lently used matrix was the medication possession ratio (MPR), adopted by 46 research studies, and the prescription days covered (PDC), which were applied in 31 investigations. Additionally, some research compared MPR with PDC, adjusted MPR (aMPR), refill compliance rate, compliance ratio, modified MPR (MPRm), continuous multiple interval measure-ment of oversupply, and continuous single-interval measure of medication acquisition, including other measure types such as Recomp, primary adherence, number of days covered, and prescription possession ratio. Additionally, aMPR and MPRm are modifications of the MPR matrix, personally designed to suit this investigation[45,62] (Table 1).

Table 1 Distribution of Pharmacy-Based Matrix to Measure Medication Adherence

No	Matrix	Definition	Number of Research	References
1	Medication possession ratio (MPR)	The MPR was defined as the sum total of the prescription supply dispensed between the first and last pharmacy fill (with the last fill excluded), divided by the number of days between the prescriptions.	46	[45–47, 49, 51, 53, 59–62, 64, 69, 71–75, 79–82, 84–88, 91, 94, 96–109, 111–114]
2	Proportion of days covered (PDC)	PDC referred to the number of days covered, divided by the total in time period x 100.	31	[43–45, 47, 48, 50, 52–56, 58, 62, 63, 65–68, 70, 71, 76, 77, 84, 87, 92, 93, 110, 115–117]
3	Modified medication possession ratio (MPRm)	MPRm was the number of supply days, divided (Last claim date − index date) + last refill supply x 100	1	[45]
4	Refill compliance rate (RCR)	The RCR was defined as the number of supply days divided by the last claim date x 100	1	[45]
5	Compliance ratio (CR)	The CR referred to the number of days supply in index period − last refill supply, divided by the Last claim date − index date	1	[45]
6	Continuous multiple-interval measurement of oversupply (CMOS)	The CMOS was the Total days of medication gaps, divided by Total days to next fill or end of observation period	1	[45]
7	Continuous single interval measure of medication acquisition (CSA)	The CSA referred to the days supply obtained at the beginning of the interval, divided by days in the interval	1	[45]
8	Adjusted MPR (aMPR)	In order to calculate the aMPR, the MPR of each patient must be known. This was multiplied by an adjustment factor. Furthermore, the factor of each drug product type is the ratio of the average number of days between refills of 1 drug product divided by the average days supply recorded for the same drug product.	1	[62]

(*Continued*)

Table 1 (Continued).

No	Matrix	Definition	Number of Research	References
9	ReComp	The ReComp (Refill Compliance) calculation is a measure used to determine medication adherence over a period. This was determined by the Total number of days medication available, divided by the total number of days in the measurement period.	1	[95]
10	Primary adherence	Primary adherence rate was expressed as the number of pharmacy claims records divided by the total number of pre- scription records	1	[57]
11	Number of days covered	The number of days covered was defined as the number of days in the follow-up period during which the index medication was determined to be handy based on the pharmacy claim fill date plus days supply	1	[83]
12	Prescription possession ratio (PPR)	PPR was defined by dividing the number of days prescribed during the calendar year by the number of days in the interval. This is equivalent to the proportion of days in the year when the drug was prescribed	1	[89]

Study Outcomes

Suitability

The suitability of the pharmacy-based measures was assessed based on the characteristics associated with validity and applicability. Our systematic review revealed that two articles describe pharmacy-based measures as a comprehensive method,[44,51] and 16 studies emphasize its accuracy,[44,53,55,69,71,72,80,84,85,87,90,94,95,102,103,114] (Table S2). The next validity characteristic is ensuring a reliable and objective assessment, where three studies report reliable MPR and PDC matrix measures,[85,109] whereas 30 studies highlight its objectivity,[46,47,51,54,60,61,64,66,69,72,74,75,77,79–81,85,87,88,90,94,95,97,98,105,106,108,114,115] (Table S2). Furthermore, 73 studies demonstrated that pharmacy-based measures can maintain a continuous adherence history,[43–45,47–50,52,53,55–59,61–63,66–68, 70,71,73,75,76,78,80,82–84,86,88,89,91–93,95,96,98–104,106,109–111,113,115,117] (Table S2). Additionally, two studies noted that PDC and MPR were unobtrusive enough to prevent influencing patient behavior,[72] and seven studies supported high-sensitivity pharmacy-based measures,[48,73,76,93,96,97,99] (Table S2). Moreover, this systematic review uncovered further evidence supporting the validity of pharmacy-based adherence measures (Table S2). Specifically, one study indicated that medication adherence estimations are more accurate when the PDC is combined with the primary adherence matrix[78] (Table S2). Seven studies refer to this method as a validated approach for measuring medication adherence[45,70,79,85,104,110,117] whereas one study describes it as a standardized approach for adherence assessment[70] (Table S2). Another study established standard thresholds that correlated with enhanced health outcomes[43] (Table S2). Further support includes one study conducting a comparative analysis[49] and one study indicating that this adherence measurement method is unaffected by recall bias,[100] (Table S2). However, one study in this review revealed that pharmacy-based measures were not valid in certain contexts, specifically when evaluating medication adherence in patients with asthma.[65] This study utilized a PDC matrix and inhaler monitoring or sensor technology. Inhaler sensor technology provided a more objective and reliable measurement by directly capturing accurate data on medication use and adherence patterns. This technology enabled adherence to prescribed doses to be independently assessed, providing a more precise adherence measurement than pharmacy-based methods alone.[65]

In terms of applicability, our systematic review determined 3 studies indicating that it is inexpensive,[59,61,106] 39 studies demonstrating that this method is easy to interpret,[43–45,47,48,52–56,58,59,61–63,66,67,70,71,73,75–77,82–84,86,88,93,95, 97–99,101,102,104,105,113,114] and 7 studies exhibiting that it is easy to use,[45,51,52,59,72,84,91] (Table S2). Additionally, we uncovered further evidence that supports the applicability of the pharmacy-based medication adherence measurement

method: 47 studies emphasized its suitability for large populations,[46–49,56,57,60–68,70,71,75,77,78,80,81,83,85,86,89,90][92–95,97–99,101,102,104,105,108,110–112,117] 1 study revealed that longer study intervals improve refill adherence measurement accuracy,[90] 5 studies denoted that it can track medication adherence during prescription switches and overlapping fills,[55,77,96,105,113] and 4 studies showed that it can measure adherence in both mono- and dual-therapy settings,[44,77,105,113] (Table S2). Furthermore, 1 study revealed early nonadherence detection[57] 5 affirmed its use of real-world data,[50,87,89,100,109] 3 noted its utility in tracking long-term medication adherence,[69,111,113] 1 confirmed feasibility to implement in clinical use, and 2 validated its effectiveness for patients with chronic diseases,[49,55] (Table S2) Additionally, 1 study revealed that it minimizes the Hawthorne effect[72] another emphasized the completeness of data from pharmacy dispensing records compared to health center prescriptions,[104] 1 study indicated that refill behavior aligns with actual medication use,[98] and 1 supported its effectiveness in chronic condition adherence measurement.[49] (Table S2). Integrating pharmacy claims databases across multiple pharmacies further improved the reliability of adherence measurements[44] (Table S2). One study indicated that pharmacy-based measures are effectively applied to evaluate medication adherence among patients with asthma and COPD, considering that the inhaler is used consistently as a control medication rather than only as needed.[106]

Quality Assessment and Publication Bias

The results revealed in the cohort investigation were within the range of 6–9 and interpreted as good quality (Table S3). The assessment of the nested case-control investigations generated a score of 9, interpreted as good quality (Table S4). The results in the cross-sectional research ranged from 7 to 10 and were categorized as good and very good (Table S5). The quality assessment result for the quasi-experimental investigation demonstrated a low risk of bias (Table S6). Results from RCTs differed in quality, ranging from poor to good (Table S7).

Discussion

Our systematic review revealed that 73 studies provided evidence of validity characteristics for pharmacy-based measures in evaluating medication adherence.[9–61,63–69,71,73–89,91–111,113–116,118–125] However, one study revealed that this method lacks validity when compared with inhaler monitoring or sensor technology. Moreover, all 74 studies emphasized that pharmacy-based methods demonstrate characteristics relevant to their applicability.[43–115]

The first aspect of determining the suitability of pharmacy-based measures for routine clinical use focuses on validity characteristics, as the methods used to measure medication adherence must be valid.[36,37,126] Moreover, validity is the ability of an instrument or tool to accurately measure the construct or outcome (medication adherence).[118] The validity characteristics of measuring medication adherence include several aspects, such as being complete and accurate, providing a reliable and objective assessment, having a continuous record of adherence history, being unobtrusive to not affect patient behavior, as well as possessing excellent sensitivity and specificity or having a statistical association.[36,37] Under the research reviewed, this method produces complete and accurate data.[44,51,53,55,71,72,74,80,84,85,87,90,94,95,102,103,114] A complete database for pharmacy-based medication adherence measurement is crucial because incomplete data cause overestimation or underestimation of the calculations, resulting in inaccurate results.[119] However, the present systematic review used all real-world data sources from primary healthcare providers, pharmacies, and national databases. This prevents recall bias, obtaining more accurate results than methods depending on subjective judgment.[30–32] Furthermore, reliability is the ability of an instrument to produce the same results whenever the measurements are repeated, thereby depicting consistency.[118] Several studies have revealed that pharmacy-based measures are reliable and consistent.[55,85,109] Moreover, reliable medication adherence measurement was utilized to ensure effective medication and optimized health outcomes, including serving as a basis for identifying appropriate interventions for patients with low adherence results.[120,127] Therefore, the data collected from measuring medication compliance must be reliable or trustworthy.

The next aspect of the validity characteristics focused on the measurement objectivity. An objective adherence measurement was conducted without being affected by subjective opinions or interpretations, both from patients and observers. Several studies have confirmed that pharmacy-based measures are an objective method.[46,47,51,60,61,66,69,72,74,75,77,][79–81,85,87,88,90,94,95,97,98,105,106,108,114,115,121] (Table S2). They aimed to prevent bias in medication adherence measurement. Additionally, some studies categorized this method as belonging to the category of objective adherence measurement.[122–124] The next validity characteristic we observed was a continuous record of adherence history. This is important. Yousif et al,

(2020) demonstrated that having records or information from past care events, such as prescriptions, enabled continuous assessment.[24] Additionally, the pharmacy-based measures relied on prescription fill records as the main data in measuring medication adherence. This method uses database sources that enable a continuous record of the adherence history. Further, this was confirmed by the observation period of each investigation, which ranged from 3 to >60 months (Table S2). The database utilized to measure medication adherence provided prescription fill history records, which served as the main data on an ongoing basis, during the observation period.[43–64,66–115], (Table S2). Fénélon–Dimanche et al (2021) indicated that an ongoing adherence history is crucial to monitoring a patient's medication adherence.[25]

Another important result was that the pharmacy-based measure was unobtrusive as well as prevented the Hawthorne effect[72] to not influencing patient behavior.[46] The Hawthorne effect is a psychological phenomenon related to a change in behavior caused by the realization of being observed or watched, resulting in biased results.[125] Preventing the Hawthorne effect improves the accuracy of estimates, causing valid medication adherence measurement data.[72] Furthermore, the pharmacy-based measure is sensitive in identifying changes in medication adherence and comparable.[48,49,73,76,96,97,99] Good sensitivity is crucial, partly because the results of measuring medication adherence tend to identify the success of intervention efforts.[22] Several strengths increased the validity of this pharmacy-based measure in addition to these aspects of validity. These include standardized pharmacy-based measure thresholds related to better health outcomes and not affected by recall bias,[43] valid methods,[45,70,79,85,104,110,117] refill behaviors that correlate with actual medication consumption, and established procedures for evaluating medication adherence.[97,116] Additionally, the estimation of medication adherence is more realistic and accurate when PDC is integrated with the primary adherence measurement.[78] Therefore, pharmacy-based measures are validated for measuring medication adherence.[43–64,66–115]

The second aspect associated with determining the suitability of pharmacy-based measures in clinical use is the applicability characteristics, which are relatively inexpensive, easy to use, and easy to interpret.[36,37] Several studies have revealed that pharmacy-based measures are relatively inexpensive based on a systematic review.[59,61,106] This is crucial because relatively expensive methods may be challenging to implement in clinical practice.[102] Additionally, pharmacy-based measures are easy to interpret, with the most prevalent cut-off being ≥80% medication adherent and <80% nonadherent.[43–45,47,48,52–56,58,59,61,63,66,67,70,71,73,75–77,82–84,86,88,93,97–99,101,102,104,105,113,114,128,129] Yousif et al (2020) revealed that an issue encountered in measuring medication adherence is a lack of objective and simply interpretable information. The use of easily interpretable medication claim data are an important facilitator in measuring medication adherence.[24] The straightforward interpretation addresses the difficulties faced in clinical applications. Pharmacy-based matrix is not only easy to interpret but also simple to utilize.[45,51,52,59,84,91,130] This simplicity is crucial for time efficiency and integration with clinical practice, which affects the assessment of medication adherence. Some clinicians reported not having enough time to comprehensively assess adherence regarding time constraints.[24] The easy usage and calculation of the pharmacy-based measure is an advantage that may resolve this issue.

Several other factors, such as the ability to measure medication adherence in single and multiple medications, supported the characteristics of the applicability of pharmacy-based measures in routine clinical use.[44,77,105,113] This method utilizes real-world data[50,87,89,100,109] and one of its matrices can be utilized for the early identification of nonadherence.[57] Additionally, the use of an integrated claims database across pharmacies increases the reliability of medication adherence measurement.[44] Additionally, this method accounts for overlapping days and medication switching,[55,77,96,105,113] including measuring adherence in large populations.[43,45,47–50,52,54,56,57,59–68,70,71,75,77–79,81,84,85,89,92–98,101,103–105,108,110–112,115,117,131] Furthermore, the accuracy of measurement increases with longer prescription fill data[90] and is used to evaluate adherence to long-term medication.[69,111,113] The richness of the data prevents bias,[106] and information obtained from pharmacies is more comprehensive than drug registration data prescribed at health centers.[104] Meanwhile, the utilization of an integrated claims database across all pharmacies improves the reliability of medication adherence measurement.[74] This method is effective for measuring adherence in patients with chronic diseases[49,55] and is feasible for clinical use.[52] The filling of prescriptions is often consistent with taking medication.[87] Pharmacy-based measures are applicable potential solutions for overcoming the issues encountered in the practice of medication measurement based on the systematic review conducted.

Another key result of this systematic review is that it improves the understanding of the applicability of pharmacy-based measures. Our results indicate that this method effectively evaluates adherence in patients with asthma, considering that the inhaler is consistently utilized as a control medication rather than only as required.[106] This information confirms

that pharmacy-based measures are applicable for measuring medication adherence in patients with asthma or COPD who depend on inhalers as part of their routine control medication.

Moreover, we gathered information on the limitations of pharmacy-based measures to understand the potential constraints in employing this method. Our results indicate that 12 studies revealed the potential for overestimation and underestimation in this approach.[43,47,57,65,67,68,78,82,91,96,100,110] However, this was countered by 16 studies revealing that pharmacy-based adherence measurement is an accurate method.[44,53,55,69,71,72,80,84,85,87,90,94,95,102,103,114] Furthermore, 28 studies demonstrated that this approach cannot directly observe patients' actual drug consumption.[44,46,52,56,63,65,71–74,77,80,83,87,88,92,94,95,99,103–106,109,111,112,114,115] However, 30 other studies emphasized that pharmacy-based adherence measurement is objective.[46,47,51,54,60,61,64,66,69,72,74,75,77,79–81,85,87,88,90,94,95,97,98,105,106,108,114,115] Thus, this method still yields objective measurement results although it cannot directly measure actual drug consumption. Excluding single fills highlighted that this approach does not account for prescriptions filled only once (single fills).[43,83] However, this limitation may not significantly affect its use for evaluating medication adherence in patients with chronic illness, as these patients typically require long-term medication, causing multiple refills throughout their treatment.[132] Additionally, two studies in this research indicated that pharmacy-based measures are effective for assessing adherence among patients with chronic illness.[49,55] Additionally, we revealed that pharmacy-based measures could not capture medication switching.[43] However, we revealed that some previously reviewed studies revealed that pharmacy-based measures could capture medication switching adherence.[55,77,96,105,113] Our research determined some limitations in pharmacy-based measures, but a greater number of studies emphasized significant strengths of this method that address these drawbacks. Consequently, pharmacy-based measures are both relevant and suitable as a tool for assessing medication adherence in routine clinical use because of these benefits.

Strength and Limitations

This study is the first to determine the suitability of pharmacy-based measures for clinical use. Additionally, the review focused on five chronic diseases with high prevalence globally, namely hypertension, hyperlipidemia, asthma, COPD, and DM. The year and type of study design were not restricted, causing a comprehensive collection and review of information. Additionally, we provided information on the drawbacks of pharmacy-based measures that may influence their use in routine clinical settings. However, our review revealed that a greater number of studies highlighted the method's significant strengths that answer these limitations. Additionally, this study has limitations; only two databases were searched, indicating that some investigations may have been missed.

Conclusion

This systematic review demonstrates that pharmacy-based measures possess valid characteristics, including comprehensive, accurate, objective, reliable, and continuously updated adherence history records. These measures are designed to minimize disruption while offering high sensitivity and specificity. Furthermore, they are characterized by their practicality, being cost-effective, easy to implement, and easy to interpret. These findings suggest that pharmacy-based measures are potentially suitable to assess medication adherence for routine clinical use.

Acknowledgments

Funding

Disclosure

The authors declare no conflicts of interest in this work.

References

1. WHO.*Action Plan for the Prevention and Control of Noncommunicable Diseases in South-East Asia, 2013–2020*. World Health Organization, Regional Office for South-East Asia; 2021. http://apps.who.int/bookorders.
2. WHO. Noncommunicable Diseases. *N Engl J Med*. 2013;11:9345. doi:10.1056/nejmra1109345
3. WHO. Hypertension. 2023. Accessed November 16, 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension.
4. World Health Organization. Asthma. 2023. Accessed Nov 16, 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma#:~:text.
5. WHO. The top 10 causes of death. 2020. Accessed November 16, 2023. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death%0Ahttp://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=5488.
6. WHO. More Than 700 Million People with Untreated Hypertension. 2021. Accessed November 16, 2023. Available from: https://www.who.int/news/item/25-08-2021-more-than-700-million-people-with-untreated-hypertension#:~:text.
7. Hill MF, Bordoni B. Hyperlipidemia. 2023. Accessed November 16, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559182/.
8. CDC. *National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP); About Chronic Disease*. Center for Disease Control and Prevention. doi:10.4135/9781412963855.n811
9. Burnier M. The role of adherence in patients with chronic diseases. *Eur J Intern Med*. 2023;23(00233–9):1. doi:10.1016/j.ejim.2023.07.008
10. Alosaimi K, Alwafi H, Alhindi Y, et al. Medication Adherence among Patients with Chronic Diseases in Saudi Arabia. *Int J Environ Res Public Health*. 2022;19(16):1–9. doi:10.3390/ijerph191610053
11. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. *Patient Prefer Adherence*. 2016;10:1299–1306. doi:10.2147/PPA.S106821
12. Alfian SD, Denig P, Coelho A, Hak E, Bachschmid MM. Pharmacy-based predictors of non-adherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands. *PLoS One*. 2019;14(11):e0225390. doi:10.1371/journal.pone.0225390
13. Kengne AP, Brière JB, Zhu L, et al. Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review. *Expert Rev Pharmacoecon Outcomes Res*. 2023;2023:1–12. doi:10.1080/14737167.2023.2266135
14. Stewart SJF, Moon Z, Horne R. Medication nonadherence: health impact, prevalence, correlates and interventions. *Psychol Heal*. 2023;38(6):726–765. doi:10.1080/08870446.2022.2144923
15. Martell Claros N. Importance of adherence in the management of hypertension. *Hipertens Riesgo Vasc*. 2023;40(1):34–39. doi:10.1016/j.hipert.2022.06.002
16. Ali AOA, Prins MH. Mobile health to improve adherence to tuberculosis treatment in Khartoum state, Sudan. *J Public Health Africa*. 2019;10(2):1. doi:10.4081/jphia.2019.1101
17. Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug–Related Morbidity and Mortality. *Ann Pharmacother*. 2018;52(9):829–837. doi:10.1177/1060028018765159
18. Alfian SD, Sukandar H, Lestari K, Abdulah R. Medication Adherence Contributes to an Improved Quality of Life in Type 2 Diabetes Mellitus Patients: a Cross-Sectional Study. *Diabetes Ther*. 2016;7(4):755–764. doi:10.1007/s13300-016-0203-x
19. Permenkes RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 73 Tahun 2016 Tentang Standar Pelayanan Kefarmasaian Di Apotek. *Kementrian Kesehatan Republik Indonesia*. 2016;2016:1.
20. McFarland MS, Finks SW, Smith L, Buck ML, Ourth H, Brummel A. Medication optimization: integration of comprehensive medication management into practice. *Am Heal Drug Benefits*. 2021;14(3):111–114.
21. Ayu GA, Syaripuddin M. Peranan Apoteker dalam Pelayanan Kefarmasian pada Penderita Hipertensi. *J Kedokt Dan Kesehat*. 2019;15(1):10. doi:10.24853/jkk.15.1.10-21
22. Elnaem MH, Rosley NFF, Alhifany AA, Elrggal ME, Cheema E. Impact of pharmacist-led interventions on medication adherence and clinical outcomes in patients with hypertension and hyperlipidemia: a scoping review of published literature. *J Multidiscip Healthc*. 2020;13:635–645. doi:10.2147/JMDH.S257273
23. Presley B, Groot W, Pavlova M. Pharmacists' and patients' perceptions about the importance of pharmacist services types to improve medication adherence among patients with diabetes in Indonesia. *BMC Health Serv Res*. 2021;21(1):1227. doi:10.1186/s12913-021-07242-1
24. Yousif A, Eláez S, Lemière C, et al. Development of a web-based tool built from pharmacy claims data to assess adherence to respiratory medications in primary care. *Respir Care*. 2020;65(9):1355–1366. doi:10.4187/respcare.07328
25. Fénélon-Dimanche R, Guénette L, Trudel-Bourgault F, et al. Development of an electronic tool (e-AdPharm) to address unmet needs and barriers of community pharmacists to provide medication adherence support to patients. *Res Soc Adm Pharm*. 2021;17(3):506–513. doi:10.1016/j.sapharm.2020.04.022
26. Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. *BMC Med Res Methodol*. 2011;11:11. doi:10.1186/1471-2288-11-149
27. Khoiry QA, Alfian SD, van Boven JFM, Abdulah R. Self-Reported Medication Adherence Instruments and Their Applicability in Low-Middle Income Countries: a Scoping Review. *Frontiers in Public Health*. 2023;11:1104510. doi:10.3389/fpubh.2023.1104510
28. Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. *Transl Behav Med*. 2015;5(4):470–482. doi:10.1007/s13142-015-0315-2
29. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. *Med Pharm Reports*. 2019;92(2):117–122. doi:10.15386/mpr-1201
30. Lam WY, Fresco P. Medication Adherence Measures: an Overview. *Biomed Res Int*. 2015;2015:1–12. doi:10.1155/2015/217047

31. Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider. *Int J Clin Pharm*. 2014;36(1):55–69. doi:10.1007/s11096-013-9865-x

32. Basu S, Garg S, Sharma N, Meghachandra Singh M. Improving the assessment of medication adherence: challenges and considerations with a focus on low-resource settings. *Tzu Chi Med J*. 2019;31(2):73–80. doi:10.4103/tcmj.tcmj_177_18

33. Schnorrerova P, Matalova P, Wawruch M. Medication adherence: measurement methods and approaches. *Bratisl Med J*. 2024;125(4):264–273. doi:10.4149/BLL

34. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:1. doi:10.1136/bmj.n71

35. Fontanet CP, Choudhry NK, Isaac T, et al. Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data. *Health Serv Res*. 2022;57(3):524–536. doi:10.1111/1475-6773.13714

36. Al-Hassany L, Kloosterboer SM, Dierckx B, Koch BC. Assessing methods of measuring medication adherence in chronically ill children-a narrative review. *Patient Prefer Adherence*. 2019;13:1175–1189. doi:10.2147/PPA.S200058

37. Farmer KC. Methods for Measuring and Monitoring Medication Regimen Adherence in Clinical Trials and Clinical Practice. *Clin Ther*. 1999;21(6):1074–1090. doi:10.1016/S0149-2918(99)80026-5

38. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev*. 2016;5(1):210. doi:10.1186/s13643-016-0384-4

39. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital. 2021. Accessed June 11, 2024. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

40. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Á G. Are healthcare workers intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC Public Health*. 2013;13(1). doi:10.1186/1471-2458-13-154

41. Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. *Dement Geriatr Cognit Disord*. 2001;12(3):232–236. doi:10.1159/000051263

42. Seo HJ, Kim SY, Lee YJ, Park JE. RoBANS 2: a Revised Risk of Bias Assessment Tool for Nonrandomized Studies of Interventions. *Korean J Fam Med*. 2023;44(5):249–260. doi:10.4082/kjfm.23.0034

43. Jackson SL, Nair PR, Chang A, et al. Antihypertensive and statin medication adherence among Medicare Beneficiaries. *Am J Prev Med*. 2022;63(3):313–323. doi:10.1016/j.amepre.2022.02.019.Antihypertensive

44. Serhal S, Armour C, Billot L, et al. Integrating Pharmacy and Registry Data Strengthens Clinical Assessments of Patient Adherence. *Front Pharmacol*. 2022;13:1–13. doi:10.3389/fphar.2022.869162

45. Burger JR, Obeng-Kusi M, Lubbe MS, Cockeran M. Comparison of adherence measures using claims data in the South African private health sector. *S Afr Med J*. 2020;110(9):932–936. doi:10.7196/SAMJ.2020.v110i9.14189

46. Wolever RQ, Dreusicke MH. Integrative health coaching: a behavior skills approach that improves hba1c and pharmacy claims-derived medication adherence. *BMJ Open Diabetes Res Care*. 2016;4(1):e000201. doi:10.1136/bmjdrc-2016-000201

47. Lim MT, Ab Rahman N, Teh XR, et al. Optimal cut-off points for adherence measure among patients with type 2 diabetes in primary care clinics: a retrospective analysis. *Ther Adv Chronic Dis*. 2021;12:2040622321990264. doi:10.1177/2040622321990264

48. Borah BJ, Qiu Y, Shah ND, Gleason PP. Impact of provider mailings on medication adherence by Medicare Part D members. *Healthcare*. 2016;4(3):207–216. doi:10.1016/j.hjdsi.2016.02.004

49. Jung K, McBean AM, Kim J-A. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs. *J Manag Care Pharm*. 2012;18(2):106–115. doi:10.18553/jmcp.2012.18.2.106

50. Schmittdiel JA, Nichols GA, Dyer W, Steiner JF, Karter AJ, Raebel MA. Health care system-level factors associated with performance on medicare STAR adherence metrics in a large, integrated delivery system. *Med Care*. 2015;53(4):332–337. doi:10.1097/MLR.0000000000000328

51. Cohen HW, Shmukler C, Ullman R, Rivera CM, Walker EA. Measurements of medication adherence in diabetic patients with poorly controlled HbA1c. *Diabet Med*. 2010;27(2):210–216. doi:10.1111/j.1464-5491.2009.02898.x

52. Yousif A, Lemière C, Forget A, Beauchesne MF, Blais L. Feasibility of implementing a web-based tool built from pharmacy claims data (e-MEDRESP) to monitor adherence to respiratory medications in primary care. *Curr Med Res Opin*. 2022;38(12):2055–2067. doi:10.1080/03007995.2022.2135835

53. Prabhu K, Salwe KJ, Saravanabavan N, Manimekalai K. Medication Adherence using Medication Possession Ratio and Proportion of Days Covered among Elderly Diabetic Patients Visiting a Tertiary Care Hospital in Puducherry. *Biomed Pharmacol J*. 2023;16(1):179–188. doi:10.13005/bpj/2599

54. Daugherty SL, Helmkamp L, Vupputuri S, et al. Effect of Values Affirmation on Reducing Racial Differences in Adherence to Hypertension Medication: the HYVALUE Randomized Clinical Trial. *JAMA Network Open*. 2021;4(12):1–22. doi:10.1001/jamanetworkopen.2021.39533

55. Torres-Robles A, Wiecek E, Cutler R, et al. Using dispensing data to evaluate adherence implementation rates in community pharmacy. *Front Pharmacol*. 2019;10(FEB):1–9. doi:10.3389/fphar.2019.00130

56. Gooptu A, Taitel M, Laiteerapong N, Press VG. Association between medication non-adherence and increases in hypertension and type 2 diabetes medications. *Healthc*. 2021;9(8):976. doi:10.3390/healthcare9080976

57. Coelho A. Linkage between electronic prescribing data and pharmacy claims records to determine primary adherence: the case of antihypertensive therapy in the Lisbon and Tagus Valley Region, Portugal. *Fam Pract*. 2023;40(2):248–254. doi:10.1093/fampra/cmac109

58. Genelin MP, Helmkamp LJ, Steiner JF, et al. Patient Pill Organization Strategies and Adherence Measured in a Cross-Sectional Study of Hypertension. *Patient Prefer Adherence*. 2023;17:817–826. doi:10.2147/PPA.S399693

59. Puspitasari IM, Azizah LN, Sinuraya RK, Alfian SD, Abdulah R. Measuring medication adherence of hypertensive patients with monotherapy treatment in a community health center by utilizing medication possession ratio. *Pharmacia*. 2022;69(2):345–350. doi:10.3897/PHARMACIA.69.E82330

60. Chepulis L, Mayo C, Morison B, et al. Metformin adherence in patients with type 2 diabetes and its association with glycated haemoglobin levels. *J Prim Health Care*. 2020;12(4):318–326. doi:10.1071/HC20043

61. Herskind J, Zelasko J, Bacher K, Holmes D. The outpatient management of hypertension at two Sierra Leonean health centres: a mixed-method investigation of follow-up compliance and patient-reported barriers to care. *African J Prim Heal Care Fam Med*. 2020;12(1):1–7. doi:10.4102/phcfm.v12i1.2222

62. Zhang H, Barner JC, Moczygemba LR, Rascati KL. Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes. *J Manag Care Spec Pharm*. 2020;26(11):1434–1444. doi:10.18553/JMCP.2020.26.11.1434

63. Hong M, Esse T, Vadhariya A, et al. Evaluating success factors of a medication adherence tracker pilot program in improving part D medication adherence metrics in a Medicare advantage plan: importance of provider engagement. *J Manag Care Spec Pharm*. 2020;26(5):662–667. doi:10.18553/jmcp.2020.26.5.662

64. Michiels Y, Bugnon O, Chicoye A, et al. Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: a Cluster Randomized Controlled Study. *Adv Ther*. 2019;36(6):1291–1303. doi:10.1007/s12325-019-00957-y

65. Stanford RH, Averell CM, Johnson PT, Buysman EK, Carlyle MH. Adherence and usage patterns of inhaled corticosteroids- long-acting beta-agonists by using inhaler-monitoring technology. *Allergy Asthma Proc*. 2020;41(1):256–264. doi:10.2500/aap.2020.41.200037

66. Wolf MS, Taitel MS, Jiang JZ, et al. Prevalence of Universal Medication Schedule prescribing and links to adherence. *Am J Heal Pharm*. 2020;77(3):196–205. doi:10.1093/ajhp/zxz305

67. Kim NH, Look KA. The effect of reduced drug copayments on adherence to oral diabetes medications among childless adults in Wisconsin Medicaid. *J Manag Care Spec Pharm*. 2019;25(12):1432–1441. doi:10.18553/jmcp.2019.25.12.1432

68. Mann A, Esse TW, Serna O, Castel LD, Abughosh SM. Effectiveness of mailed letters to improve medication adherence among medicare advantage plan participants with chronic conditions. *Patient Prefer Adherence*. 2019;13:37–46. doi:10.2147/PPA.S185848

69. Tan BY, Shafie AA, Hassali MAA, Saleem F, Muneswarao J. Improving medication adherence through calendar packaging: results of a randomized controlled trial among hypertensive patients. *J Pharm Heal Serv Res*. 2017;8(2):115–122. doi:10.1111/jphs.12171

70. Winslade N, Tamblyn R. Determinants of community pharmacists' quality of care: a population-based cohort study using pharmacy administrative claims data. *BMJ Open*. 2017;7(9):e015877. doi:10.1136/bmjopen-2017-015877

71. Oung AB, Kosirog E, Chavez B, Brunner J, Saseen JJ. Evaluation of medication adherence in chronic disease at a federally qualified health center. *Ther Adv Chronic Dis*. 2017;8(8–9):113–120. doi:10.1177/2040622317714966

72. du Pon E, El Azzati S, van Dooren A, Kleefstra N, Heerdink E, van Dulmen S. Effects of a proactive interdisciplinary self-management (PRISMA) program on medication adherence in patients with type 2 diabetes in primary care: a randomized controlled trial. *Patient Prefer Adherence*. 2019;13:749–759. doi:10.2147/PPA.S188703

73. Bidwal M, Lor K, Yu J, Ip E. Evaluation of asthma medication adherence rates and strategies to improve adherence in the underserved population at a Federally Qualified Health Center. *Res Soc Adm Pharm*. 2017;13(4):759–766. doi:10.1016/j.sapharm.2016.07.007

74. Tan BY, Shafie AA, Hassali MAA, Saleem F. Assessment of medication adherence and the costs associated with a calendar blister pack intervention among hypertensive patients in Malaysia: a randomized controlled trial. *SAGE Open Med*. 2017;5:2050312117709189. doi:10.1177/2050312117709189

75. Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. *Diabetes Care*. 2016;39(2):258–263. doi:10.2337/dc15-1194

76. Peaslee A, Wickizer M, Olson J, Topp R. Impact of a combined value-based insurance design and medication therapy management program on diabetes medication adherence. *J Manag Care Spec Pharm*. 2016;22(11):1303–1309. doi:10.18553/jmcp.2016.22.11.1303

77. Piercefield EW, Howard ME, Robinson MH, Kirk CE, Ragan AP, Reese SD. Antihypertensive medication adherence and blood pressure control among central Alabama veterans. *J Clin Hypertens*. 2017;19(5):543–549. doi:10.1111/jch.12953

78. Blais L, Kettani FZ, Forget A, Beauchesne MF, Lemière C, Ducharme FM. Assessing adherence to inhaled corticosteroids in asthma patients using an integrated measure based on primary and secondary adherence. *Eur J Clin Pharmacol*. 2017;73(1):91–97. doi:10.1007/s00228-016-2139-5

79. Machado-Alba JE, Medina-Morales DA, Echeverri-Cataño LF. Comparison of medication adherence in diabetes mellitus patients on human versus analogue insulins. *Expert Opin Drug Saf*. 2017;16(2):133–137. doi:10.1080/14740338.2017.1273346

80. De Leon SF, Pauls L, Arya V, Shih SC, Singer J, Wang JJ. Effect of physician participation in a multi-element health information and data exchange program on chronic illness medication adherence. *J Am Board Fam Med*. 2015;28(6):742–749. doi:10.3122/jabfm.2015.06.150010

81. Vasbinder EC, Belitser SV, Souverein PC, van Dijk L, Vulto AG, van den Bemt PMLAPMLA. Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children. *Patient Prefer Adherence*. 2016;10:531–538. doi:10.2147/PPA.S92824

82. Rash JA, Lavoie KL, Sigal RJ, et al. The OPTIMIZE trial: rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. *Contemp Clin Trials*. 2016;49:47–56. doi:10.1016/j.cct.2016.06.001

83. Bibeau WS, Fu H, Taylor AD, Kwan AYM. Impact of out-of-pocket pharmacy costs on branded medication adherence among patients with type 2 diabetes. *J Manag Care Spec Pharm*. 2016;22(11):1338–1347. doi:10.18553/jmcp.2016.22.11.1338

84. Feehan M, Ranker L, Durante R, et al. Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain. *J Clin Pharm Ther*. 2015;40(5):590–593. doi:10.1111/jcpt.12316

85. Guénette L, Breton MC, Grégoire JP, et al. Effectiveness of an asthma integrated care program on asthma control and adherence to inhaled corticosteroids. *J Asthma*. 2015;52(6):638–645. doi:10.3109/02770903.2014.999084

86. De Vera MA, Sadatsafavi M, Tsao NW, et al. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. *Trials*. 2014;15(1). doi:10.1186/1745-6215-15-488

87. Zhu VJ, Tu W, Rosenman MB, Overhage JM. A Comparison of Data Driven-based Measures of Adherence to Oral Hypoglycemic Agents in Medicaid Patients. *AMIA Annu Symp Proc*. 2014;2014:1294–1301.

88. Nair P, Kee KW, Mah CS, Lee ES. Evaluating the Impact of Outpatient Multi-Dose Medication Packaging Service (MDMPS) on Medication Adherence and Clinical Outcomes. *J Prim Care Community Heal*. 2020;11:2150132720965085. doi:10.1177/2150132720965085

89. Taylor A, Chen LC, Smith MD. Adherence to inhaled corticosteroids by asthmatic patients: measurement and modelling. *Int J Clin Pharm*. 2014;36(1):112–119. doi:10.1007/s11096-013-9862-0

90. Bender BG, Cvietusa PJ, Goodrich GK, et al. Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment a randomized clinical trial. *JAMA Pediatr*. 2015;169(4):317–323. doi:10.1001/jamapediatrics.2014.3280

91. Moczygemba LR, Barner JC, Lawson KA, et al. Impact of telephone medication therapy management on medication and health-related problems, medication adherence, and medicare part D drug costs: a 6-month follow up. *Am J Geriatr Pharmacother*. 2011;9(5):328–338. doi:10.1016/j.amjopharm.2011.08.001

92. Iyengar R, Henderson R, Visaria J, Frazee SG. Dispensing channel and medication adherence: evidence across 3 therapy classes. *Am J Manag Care*. 2013;19(10):798–804.

93. Raebel MA, Carroll NM, Ellis JL, Schroeder EB, Bayliss EA. Importance of including early nonadherence in estimations of medication adherence. *Ann Pharmacother*. 2011;45(9):1053–1060. doi:10.1345/aph.1Q146

94. Elkout H, Helms PJ, Simpson CR, McLay JS. Adequate levels of adherence with controller medication is associated with increased use of rescue medication in asthmatic children. *PLoS One*. 2012;7(6). doi:10.1371/journal.pone.0039130

95. Cecere LM, Slatore CG, Uman JE, et al. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). *COPD J Chronic Obstr Pulm Dis*. 2012;9(3):251–258. doi:10.3109/15412555.2011.650241

96. Barner JC. Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy. *Clin Ther*. 2011;33(9):1281–1288. doi:10.1016/j.clinthera.2011.07.016

97. Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, Newhouse JP. The impact of medicare part D on medication adherence among older adults enrolled in medicare-advantage products. *Med Care*. 2010;48(5):409–417. doi:10.1097/MLR.0b013e3181d68978

98. Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. *Manag Care*. 2009;18(7):47–53.

99. Odegard PS, Christensen DB. MAP study: RCT of a medication adherence program for patients with type 2 diabetes. *J Am Pharm Assoc*. 2012;52(6):753–762. doi:10.1331/JAPhA.2012.11001

100. Jentzsch NS, Camargos PAM, Colosimo EA, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. *Allergy Eur J Allergy Clin Immunol*. 2009;64(10):1458–1462. doi:10.1111/j.1398-9995.2009.02037.x

101. Jing S, Naliboff A, Kaufman MB, Choy M. Descriptive analysis of mail interventions with physicians and patients to improve adherence with antihypertensive and antidiabetic medications in a mixed-model managed care organization of commercial and medicare members. *J Manag Care Pharm*. 2011;17(5):355–366. doi:10.18553/jmcp.2011.17.5.355

102. Warren J, Warren D, Yang HY, et al. Prescribing history to identify candidates for chronic condition medication adherence promotion. In: *Studies in Health Technology and Informatics*. 2011;169:634–638. doi:10.3233/978-1-60750-806-9-634

103. Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BHR, Stolk RP, Denig P. Medication Adherence Affects Treatment Modifications in Patients With Type 2 Diabetes. *Clin Ther*. 2011;33(1):121–134. doi:10.1016/j.clinthera.2011.01.024

104. Haupt D, Weitoft GR, Nilsson JLG. Refill adherence to oral antihyperglycaemic drugs in Sweden. *Acta Diabetol*. 2009;46(3):203–208. doi:10.1007/s00592-008-0076-1

105. Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. *Clin Ther*. 2008;30(10):1893–1907. doi:10.1016/j.clinthera.2008.10.003

106. D'Souza AO, Rahnama R, Regan TS, Common B, Burch S. The H-E-B value-based health management program: impact on asthma medication adherence and healthcare cost. *Am Heal Drug Benefits*. 2010;3(6):394–402.

107. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. *Am J Manag Care*. 2008;14(2):71–75.

108. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. *J Manag Care Pharm*. 2006;12(6):466–471. doi:10.18553/jmcp.2006.12.6.466

109. Kelloway JS, Wyatt R, DeMarco J, Adlis S. Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids. *Ann Allergy Asthma Immunol*. 2000;84(3):324–328. doi:10.1016/S1081-1206(10)62781-0

110. Marupuru S, Dhatt H, Bingham JM, Warholak T. Evaluation of a Novel Pharmacist-Delivered Adherence. *Pharmacy*. 2021;9(140):1–7. doi:10.3390/pharmacy9030140

111. Vincze G, Barner JC, Bohman T, et al. Use of antihypertensive medications among United States veterans newly diagnosed with hypertension. In: *Current Medical Research and Opinion*. 2008;Vol. 24:795–805. doi:10.1185/030079908X273039

112. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. *Clin Ther*. 2002;24(3):460–467. doi:10.1016/S0149-2918(02)85047-0

113. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. *Clin Ther*. 2004;26(12):2066–2075. doi:10.1016/j.clinthera.2004.12.018

114. Adouni Lawani M, Zongo F, Breton MC, et al. Factors associated with adherence to asthma treatment with inhaled corticosteroids: a cross-sectional exploratory study. *J Asthma*. 2018;55(3):318–329. doi:10.1080/02770903.2017.1326131

115. Wong MCS, Tam WWS, Cheung CSK, et al. Medication adherence to first-line antihypertensive drug class in a large Chinese population. *Int J Cardiol*. 2013;167(4):1438–1442. doi:10.1016/j.ijcard.2012.04.060

116. Kearney SM, Aldridge AP, Castle NG, Peterson J, Pringle JL. The association of job strain with medication adherence is your job affecting your compliance with a prescribed medication regimen? *J Occup Environ Med*. 2016;58(7):707–711. doi:10.1097/JOM.0000000000000733

117. Hernández-Muñoz JJ, Wong ES, Kamdar CR. Prevalence of statin utilization and adherence among privately insured subjects in the Commonwealth of Puerto Rico. *J Manag Care Spec Pharm*. 2021;27(3):392–398. doi:10.18553/JMCP.2021.27.3.392

118. Shah KK, Touchette DR, Marrs JC. Research and scholarly methods: measuring medication adherence. *JACCP J Am Coll Clin Pharm*. 2023;6 (4):416–426. doi:10.1002/jac5.1771

119. Vermeire E, Hearnshaw H, Royen V, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. *J Clin Pharm Ther*. 2001;2001(36):331–342. doi:10.1590/s1983-14472010000400016

120. Alwhaibi M, Altoaimi M, Alruthia Y, et al. Adherence to statin therapy and attainment of LDL cholesterol goal among patients with type 2 diabetes and dyslipidemia. *Patient Prefer Adherence*. 2019;13:2111–2118. doi:10.2147/PPA.S231873

121. Lubick N. Drugs in the environment: do pharmaceutical take-back programs make a difference? *Environ Health Perspect Environ Health Perspect*. 2010;118(5):1.

122. Wouters H, Rhebergen D, Vervloet M, et al. Distinct Profiles on Subjective and Objective Adherence Measures in Patients Prescribed Antidepressants. *Drugs*. 2019;79(6):647–654. doi:10.1007/s40265-019-01107-y

123. Nassar RI, Saini B, Obeidat NM, Atatreh N, Basheti IA. Assessing adherence to medications: is there a difference between a subjective method and an objective method, between using them concurrently? *Pharm Pract (Granada)*. 2022;20(4):1–7. doi:10.18549/PharmPract.2022.4.2723

124. Kalichman SC, Amaral CM, Swetzes C, et al. A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. *J Int Assoc Physicians AIDS Care*. 2009;8(6):367–374. doi:10.1177/1545109709352884

125. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. *J Clin Epidemiol*. 2014;67(3):267–277. doi:10.1016/j.jclinepi.2013.08.015

126. Vrijens B, Pironet A, Tousset E. The Importance of Assessing Drug Exposure and Medication Adherence in Evaluating Investigational Medications: ensuring Validity and Reliability of Clinical Trial Results. *Pharmaceut Med*. 2024;38(1):9–18. doi:10.1007/s40290-023-00503-w

127. Tan CS. The Need of Patient Education to Improve Medication Adherence Among Hypertensive Patients. *Malaysian J Pharm*. 2020;6(1):1–5. doi:10.52494/MOEL1486

128. Tomás CC, Oliveira E, Sousa D, et al. Proceedings of the 3rd IPLeiria's International Health Congress: Leiria, Portugal. 6–7 May 2016. *BMC Health Serv Res*. 2016;16(Suppl 3):200. doi:10.1186/s12913-016-1423-5

129. Han J, Zhang Y, No G, Urmie J. Medication adherence among chronic condition patients in the Medicaid coverage gap. *Res Soc Adm Pharm*. 2020;16(7):982–986. doi:10.1016/j.sapharm.2019.11.011

130. Du Pon E, Kleefstra N, Cleveringa F, Van Dooren A, Heerdink ER, Van Dulmen S. Effects of the Proactive Interdisciplinary Self-Management (PRISMA) Program on Online Care Platform Usage in Patients with Type 2 Diabetes in Primary Care: a Randomized Controlled Trial. *J Diabetes Res*. 2019;2019(13):749–759. doi:10.1155/2020/5013142

131. González de León B, Del Pino-Sedeño T, Serrano-Pérez P, Rodríguez ÁC, Bejarano-Quisoboni D, Trujillo-Martín MM. Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis. *BMC Psychiatry*. 2022;22(1):1–21. doi:10.1186/s12888-022-04120-w

132. Sabaté E, WHO. *Adherence to Long-Term Therapies: Evidence for Action*. World Health Organization; 2003.